NMT.001
Drug-Resistant Epilepsy
Phase 1Active
Key Facts
About Neumirna
Neumirna is a private, pre-revenue biotech pioneering a novel miRNA-targeting platform for neurological disorders. Its lead asset, NMT.001, is a clinical-stage candidate for drug-resistant epilepsy, with a preclinical program in Parkinson's disease. Backed by leading European life science investors and founded by experts in neuroscience and RNA biology, the company is positioned to advance a new class of therapeutics that address significant unmet medical needs in neurology.
View full company profileTherapeutic Areas
Other Drug-Resistant Epilepsy Drugs
| Drug | Company | Phase |
|---|---|---|
| Implantable Neuromodulation System | Cadence Neuroscience | Pre-clinical |
| Epilepsy Program | Bright Minds Biosciences | Preclinical |